On February 19, Tom Lee of Fundstrat and BitMine joined ‘Closing Bell’ on CNBC to talk about the state of the markets. Lee described the current market environment as a slow turnaround following a series of hits, including a significant downturn in the software sector and a rotation away from the MAG7. Lee noted that investors have shifted focus toward the bullet makers of AI, while a general risk-off sentiment has been magnified by a surge in gold prices. Despite this, he remains optimistic because corporate earnings have been delivered solidly and economic reports remain strong.
Lee emphasized that the current earnings season has been strong, with a large percentage of companies reporting significant beats. However, he argued that stock prices have not yet fully reflected this fundamental strength because market multiples have been pressured by external factors, including a new Fed Chair, AI-related uncertainty, and the potential for war. Lee pointed out three key traits that he is watching for a market recovery: a rotation back into the MAG7, a bottoming out of the software sector, and a bottoming out of the crypto market.
That being said, we’re here with a list of the 10 best NASDAQ growth stocks to buy for the next 2 years.
Our Methodology
We used screeners to identify stocks that have a track record of delivering earnings growth as well as positive growth expectations. We looked for companies listed on the NASDAQ that have grown their EPS by at least 20% over the trailing twelve months and are expected to grow their EPS by at least 20% over the next year. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on February 19.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10 Best NASDAQ Growth Stocks to Buy for the Next 2 Years
10. Ascendis Pharma (NASDAQ:ASND)
Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 11, Ascendis Pharma reported that it nearly doubled its total revenue for 2025 to €720 million, fueled by the rapid global adoption of its core endocrinology products. Q4 was particularly significant, as the company achieved an operating profit of €10 million and generated €73 million in operating cash flow. This was largely driven by YORVIPATH, which brought in €477 million for the full year, and the steady performance of SKYTROFA, which contributed €206 million.
Despite a full-year net loss of €228 million due to commercial investments, the company ended the year with a solid cash position of €616 million, supported by a $100 million partnership payment from Novo Nordisk. The company’s success is rooted in its proprietary TransCon tech platform, which transforms established drugs into long-acting, once-weekly prodrugs. By linking parent drugs to an inert carrier via a temporary linker, TransCon ensures a predictable and sustained release of the active medication.
This has allowed Ascendis Pharma (NASDAQ:ASND) to secure a dominant 45% share of the US long-acting growth hormone market for SKYTROFA. Management is now preparing for the next major growth phase with the anticipated FDA approval of TransCon CNP for pediatric achondroplasia, which has a PDUFA action date of February 28, 2026, and is expected to provide a new therapeutic option beyond simple linear growth.
Ascendis Pharma (NASDAQ:ASND) is a biopharmaceutical company that develops TransCon-based (Transient Conjugation) therapies for unmet medical needs in Europe, the US, and internationally.
9. MKS Inc. (NASDAQ:MKS)
MKS Inc. (NASDAQ:MKS) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 17, MKS Inc. reported revenue of $1.03 billion for Q4 2025, which is a 10% increase year-over-year. This growth was driven by the Electronics & Packaging segment, which surged 19% compared to the prior year, due to capacity expansions in chemistry and flex drilling equipment. The company concluded the full year with $3.9 billion in total revenue.
A primary driver for the company’s current success is the rapid adoption of AI technology, which is reshaping its revenue mix. AI-related boards require significantly more layers than standard smartphone components, doubling AI chemistry revenue from 5% to 10% of total chemistry sales in 2025. Additionally, the company is benefiting from a memory crunch in the semiconductor industry. As fabs expand to meet DRAM and NAND demand for AI, MKS is seeing increased orders for its RF power solutions used in high-intensity vertical channel etching.
For 2026, MKS Inc. (NASDAQ:MKS) issued Q1 revenue guidance of $1.04 billion. While the company expects a seasonal dip in specialty industrial sales due to the Lunar New Year, it is preparing for a mid-year capacity boost with the opening of a new supercenter factory in Malaysia.
MKS Inc. (NASDAQ:MKS) provides foundational technology solutions to semiconductor manufacturing, electronics & packaging, and specialty industrial applications internationally. It operates through the Vacuum, Photonics, and Material Solutions Division segments.
